Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ublituximab in combination with
lenalidomide (Revlimid®) is safe and effective in patients with B-Cell Lymphoid Malignancies
who have relapsed or are refractory after CD20 directed antibody therapy